People | January 25, 2024
BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO
An accomplished R&D leader and champion of the application of AI to drug discovery
An accomplished R&D leader and champion of the application of AI to drug discovery
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
Subscribe To Our Newsletter & Stay Updated
